IP Verse

Stable Liquid Formulation Of Amg 416 Hcl (Etelcalcetide) - EP3246017B1

PatentPatent Analysis

EP3246017

AMGEN
Application Number
EP17160312A
Filing Date
Jun 27, 2014
Status
Granted And Under Opposition
Feb 19, 2021
Grant Date
Mar 24, 2021
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3661562B1
EP3570885B1
EP4209499B1

Bibliography

The patent EP3246017B1 was granted to Amgen on Mar 24, 2021 following the initial filing on Jun 27, 2014 under the application number EP17160312A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ADALVODec 22, 2021ADMISSIBLE
STADA ARZNEIMITTELDec 22, 2021ADMISSIBLE
SYNTHONDec 22, 2021ADMISSIBLE
FRESENIUS KABI DEUTSCHLANDDec 21, 2021ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents